IPOWarriors IPO Preview for November 29 – December 3, 2021

November 29th, 2021

We’re easing our way back out of the Thanksgiving holiday, but still some IPOs worth covering, and as always, will be on high alert for a Stealth IPO…


The streaming gear is in transit, and thanks again to everyone who contributed. Looking forward to live streaming IPO debuts once everything arrives and we get some worth covering.

It’s not too late to add contributions, as I have identified some additional needs that would help me in video production (like, some video editing software):


Ok, let’s take a look at what’s on deck for this week:

Skylight Health Group (SLHG) – TBD
Rescheduled from last week, gonna just repost what I wrote: this is an uplisting from the TSX: some affordable healthcare service provider. I’m not excited about it, uplistings generally don’t do well unless they’re either a essentially a stealth-IPO in disguise (FCUV) or something super hot like crypto mining when BTC is in an uptrend (ARBK). As I’ve explained before, the pop based on any benefits provided by an uplisting is usually already priced into the share price, and plenty of existing shareholders are ready to exit. So I don’t see any reason to get particularly excited about this one.

Nuvectis Pharma (NVCT) – 12/1/2021 |2.3M Shares
The only pure-play IPO on the calendar for this week, and also rescheduled from last week. Complicated sounding biotech with 2.3M shares… something about precision medicines for oncology. I’m not gonna try to make sense of biotech IPOs anymore. 9/10 do poorly, the random one that rips is quick to fade, and if you get stuck, the bag holding process generally takes a long time to reverse, if ever. It is a Maxim Group underwritten IPO, and low-float biotechs have been in vogue, so maybe worth keeping an eye on the social buzz around this ticker and see if we see a hint of demand in the pre-debut indication process. Don’t love it, but the float is tiny, and if day traders pile in, it could rip.

Austin Gold (AUST) – 12/3/2021 | 3M Shares
Also rescheduled again and again from last week, this one is a gold prospecting company based out of Vancouver with claims in Nevada. Their website is laughably bad, with no updated information, and some pages showing error messages. Interestingly, the CEO just sold his previous gold mining company, Pretium Resources, for $2.8B at a significant premium for shareholders, so this does look somewhat legitimate. On the downside, the market has not been too friendly to Roth Capital IPOs, so I’m not sure this will get much immediate retail demand. Then again, gold is considered an inflation hedge, and perhaps that brings this one some attention. Maybe one to watch, but unless the temperature of the social buzz around this one gets hot, I’ll be watching it from the sidelines.

Intensity Therapeutics (INTS) – TBD | 1.5M Shares
This is a clinical stage biotech focused on localized cancer reduction leading to anti-cancer immune activation via direct injection into cancer tumors. I’m not familiar with the underwriters (A.G.P. and Brookline), but an ultra-low float of 1.5M shares makes this a wild-card in this trading environment. Let’s see how NVCT does, and if it rips, day traders may shift focus to this one next. The un-scheduled biotechs tend to debut on Fridays, if they don’t get rescheduled, so we should see NVCT go first, and can then assess whether this one gets targeted as a copy-cat play.

Incannex Healthcare (IXHL) – TBD | 2.5M Shares
Also scheduled for this week with no specific date assigned, so I’d expect either a Friday debut or that it gets rescheduled. Kind of an interesting play given the low float and the fact that this company focuses on research and development for synthetic cannabidiol pharmaceuticals and psychedelic medicine. What kind of turns me off on this one is that it’s an Australian company that is uplisting from the ASX, with an assignment of 25:1 ordinary shares to ADS shares, with warrants involved. We saw this a couple weeks ago with AHI, and it didn’t go well. Add to that, Roth Capital is the underwriter, and they don’t tend to get much love from the market, so I’m less likely to give this one a shot that some of the other ultra low float biotech IPOs this week (and TBH, I’m more likely to pass on any biotech IPO than play it unless I sense something highly unusual in the social buzz and buy-side demand during the pre-debut price discovery).

Be ready for a possible Stealth IPO… (GSUN? MULG?)
We’ve been hearing rumors getting hints in other plays: such as PETZ and PLIN, that indicate that the simmering tensions between China and the West are creating a sense of urgency in the minds of wealthy Chinese who are looking to move their money out of PRC-controlled accounts. For more about my theory of what is behind these “Stealth IPOs” you can read my original post on this topic from May 15, 2021 here:

With tensions rising over Taiwan, and Chinese New Years and the Winter Olympics hosted in Beijing just around the corner, there are reasons to believe that the window for the wealthy to clear their funds is quickly closing. We were able to bank serious wins in Stealth IPOs such as TIRX, UTME, CPOP, EJH, and others… so keep an eye on your inbox for updates on these potential plays, as I’ll be sending out alerts if I get wind of anything that looks suspicious. These tend to come out on Fridays as well, and debut with little warning and almost no press coverage.

I’m watching out specifically for MULG and GSUN.

Note: the information contained in this article is not financial advice, and I am not a financial advisor. This is just information to give you ideas so you can do your own research and make your own trading decisions. I will most likely be taking positions in some of the equities listed in this email. Previous success is not an indication of future performance. Trading stocks is risky, you can lose money. Good luck out there.

Play a Song - Save a Dog

Saving Dogs Costs NOTHING!    Just play music from and royalties go towards dog rescue.
The information on this site is for informational purposes only.
We are not a licensed financial advisor, and this is not financial advice.
© All rights reserved